Sanofi gets the EU’s ok for caplacizumabThe EU approved Sanofi’s Cablivi (caplacizumab) as the first antibody therapeutic to treat acquired thrombotic thrombocytopenic purpura (aTTP) on Friday. more ➔
Cancer drug cures orphan disease skin damage An FDA-approved cancer drug stops light sensitivity of the skin in Cockayne syndrome (CS), an ultra-rare hereditary disease characterised by premature aging, German researchers report. more ➔
Germany to pump €1bn into breakthrough innovationGermany’s government announced that it will create an agency for breakthrough ("jump") innovation to foster technology transfer of risky research projects with high market potential into p … more ➔
Urovant Sciences licenses OAB gene therapyUrovant Sciences has licensed the global commercialisation rights for Ion Channel Innovations’ gene therapy hMaxi-K for patients with overactive bladder (OAB) symptoms who have failed oral … more ➔
Roche and Affimed in US$5bn cancer dealRoche’s US arm Genentech has licenced Affimed NV’s ROCK platform to add multivalent antibodies, which could activate the innate immune system, to its cancer pipeline. more ➔
Foundation launches £30m awardThe British Heart Foundation (BHF) will tender £30m (€33.2m) to tackle the suffering and devastation caused by heart and circulatory diseases. more ➔
FDA greenlights Shire’s HAE mAB Takhzyro Orphan drug leader Shire plc (Dublin), has received the FDA’s approval for its antibody lanadelumab-flyo, which prevents hereditary angioedema (HAE) attacks. more ➔
Matrikines give hint to new asthma medsBlocking the extracellular matrix (ECM) enzyme leukotriene A4 hydrolase (LTA4H) dampens inflammation but promotes changes in the airways of mice with allergic asthma due to accumulation of the ECM degradation … more ➔
Novo Nordisk joins Evotec as drug discovery partnerNovo Nordisk and Evotec have joined forces to find new drugs in the lucrative diabetes and obesity markets. more ➔
Genkyotex cashes in €7.5mFrench Genkyotex SA has secured an €7.5m gross financing to expand the scope of its Phase II product GKT831 in Primary Biliary Cholangitis (PBC). more ➔
